YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
NCT ID: NCT04000737
Last Updated: 2025-04-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
62 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-01-10
Study Completion Date
2024-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT00492752
Carcinoma, Hepatocellular
COMPLETED
PHASE3
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
NCT01204177
Carcinoma, Hepatocellular
COMPLETED
PHASE2
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
NCT00812175
Carcinoma, Hepatocellular
COMPLETED
Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment
NCT03644511
Hepatocellular Carcinoma
TERMINATED
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
NCT00956436
Hepatocellular Carcinoma
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HCC patients with chronic HBV (+) (HBsAg(+)), and Child-Pugh A status will be randomized to either the study arm (YIV-906 plus sorafenib) or control arm (placebo plus sorafenib) at ratio of 2:1. Patients will be stratified according to metastatic status (extrahepatic/vascular invasion vs. none), and their ECOG performance status (0 vs. 1) at randomization.
* ARM I: Patients receive Placebo + Sorafenib
* ARM II: Patients receive YIV-906+ Sorafenib
Patients in the study arm will be treated orally each 28-day course with YIV-906 (600 mg (3 capsules) BID) + sorafenib (400 mg BID) according to the following schedule: sorafenib BID daily treatment for 28 days, and YIV-906 BID 4 days on and 3 days off weekly in each course.
All patients will be evaluated and graded for adverse events according to the NCI Common Terminology for Adverse Events, version 5.0 (CTCAE). The Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) will be used to establish disease response or progression.
The RECIST 1.1 and mRECIST will be used in a blinded independent central review (BICR) to determine the study endpoints.
Patients will be evaluated for PFS, TTP, OS, antitumor response every two cycles, and QoL and safety at the beginning of each cycle. Biomarkers are mandatory and will be studied prior to drug administration on day 1 of each cycle. TCM Syndrome Research is optional.
PK is only applicable in China study sites and limited to the first 15 male and 15 female patients. Patients will be randomized to either the study drug arm or the placebo arm (2:1 ratio). PK studied immediately prior to dose administration and at 1 hour, 2 hours, 4 hours, and 12 hours post-dose administration on Day 1 of Cycles 1.
* ARM I: Patients receive Placebo + Sorafenib
* ARM II: Patients receive YIV-906+ Sorafenib
Patients in the study arm will be treated orally each 28-day course with YIV-906 (600 mg (3 capsules) BID) + sorafenib (400 mg BID) according to the following schedule: sorafenib BID daily treatment for 28 days, and YIV-906 BID 4 days on and 3 days off weekly in each course.
All patients will be evaluated and graded for adverse events according to the NCI Common Terminology for Adverse Events, version 5.0 (CTCAE). The Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) will be used to establish disease response or progression.
The RECIST 1.1 and mRECIST will be used in a blinded independent central review (BICR) to determine the study endpoints.
Patients will be evaluated for PFS, TTP, OS, antitumor response every two cycles, and QoL and safety at the beginning of each cycle. Biomarkers are mandatory and will be studied prior to drug administration on day 1 of each cycle. TCM Syndrome Research is optional.
PK is only applicable in China study sites and limited to the first 15 male and 15 female patients. Patients will be randomized to either the study drug arm or the placebo arm (2:1 ratio). PK studied immediately prior to dose administration and at 1 hour, 2 hours, 4 hours, and 12 hours post-dose administration on Day 1 of Cycles 1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Hepatocellular Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sorafenib + YIV-906
Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
Group Type
EXPERIMENTAL
Sorafenib+YIV-906
Intervention Type
DRUG
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Sorafenib + Placebo
Patients in the placebo arm will be given sorafenib with placebo
Group Type
ACTIVE_COMPARATOR
Sorafenib+placebo
Intervention Type
DRUG
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib+YIV-906
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Intervention Type
DRUG
Sorafenib+placebo
Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PHY906
KD018
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or females ≥18 years old with ability to take oral drugs
2. Diagnosis of advanced (locally advanced or metastatic) unresectable/inoperable HCC according to the American Association for the Study of Liver Diseases (AASLD) Guidelines (Heimbach et al. 2018) or diagnosis by tissue pathology
3. Participants categorized to stage B or C based on Barcelona Clinic Liver Cancer (BCLC) staging system
4. Life expectancy of at least 3 months
5. Presence of chronic hepatitis B (HBsAg (+))
6. Never received systemic antitumor therapy
7. Patients must have at least one tumor lesion that meets both of the following criteria:
1. "Measurable disease" according to RECIST1.1, i.e. at least one measurable lesion.
2. Advanced unresectable HCC that have liver limited disease who have failed and are not candidates to local therapies; or patients with extrahepatic disease.
8. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
9. Cirrhotic status of current Child-Pugh class A. Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period
10. For patients with positive HBV-DNA and positive HBsAg, they must be treated with anti-HBV treatment (per local standard of care), as prophylaxis starting at least 1-2 weeks prior to receiving study drug and willing to continue treatment for the length of the study
11. Patients with adequate organ reserve, such as laboratory parameters:
1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\^9/L
2. Platelets ≥ 60000 x 10\^6/L
3. Hemoglobin (Hgb) ≥ 9 g/dL
4. Serum alanine amino-transferase (ALT) ≤ 5 x ULN
5. Serum Aspartate transaminase (AST) ≤ 5 x ULN
12. Adequate renal function, based upon meeting the following laboratory criteria within 7 days before randomization:
1. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40mL/min (using the Cockcroft-Gault equation: (140-age) x weight (kg)/ (serum creatinine x 72 \[mg/dL\] for males. (For females multiply by 0.85) AND
2. Urine protein/creatine ratio (UPCR) ≤ 1 mg/mg (≤113.1 mg/mmol) or 24-hour urine protein \<1 g
13. Ability to understand and willingness to sign a written informed consent and to be able to follow the visit schedule
2. Diagnosis of advanced (locally advanced or metastatic) unresectable/inoperable HCC according to the American Association for the Study of Liver Diseases (AASLD) Guidelines (Heimbach et al. 2018) or diagnosis by tissue pathology
3. Participants categorized to stage B or C based on Barcelona Clinic Liver Cancer (BCLC) staging system
4. Life expectancy of at least 3 months
5. Presence of chronic hepatitis B (HBsAg (+))
6. Never received systemic antitumor therapy
7. Patients must have at least one tumor lesion that meets both of the following criteria:
1. "Measurable disease" according to RECIST1.1, i.e. at least one measurable lesion.
2. Advanced unresectable HCC that have liver limited disease who have failed and are not candidates to local therapies; or patients with extrahepatic disease.
8. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
9. Cirrhotic status of current Child-Pugh class A. Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period
10. For patients with positive HBV-DNA and positive HBsAg, they must be treated with anti-HBV treatment (per local standard of care), as prophylaxis starting at least 1-2 weeks prior to receiving study drug and willing to continue treatment for the length of the study
11. Patients with adequate organ reserve, such as laboratory parameters:
1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\^9/L
2. Platelets ≥ 60000 x 10\^6/L
3. Hemoglobin (Hgb) ≥ 9 g/dL
4. Serum alanine amino-transferase (ALT) ≤ 5 x ULN
5. Serum Aspartate transaminase (AST) ≤ 5 x ULN
12. Adequate renal function, based upon meeting the following laboratory criteria within 7 days before randomization:
1. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40mL/min (using the Cockcroft-Gault equation: (140-age) x weight (kg)/ (serum creatinine x 72 \[mg/dL\] for males. (For females multiply by 0.85) AND
2. Urine protein/creatine ratio (UPCR) ≤ 1 mg/mg (≤113.1 mg/mmol) or 24-hour urine protein \<1 g
13. Ability to understand and willingness to sign a written informed consent and to be able to follow the visit schedule
Exclusion Criteria
Patient who has any of the following criteria will be excluded from the trial:
1. Patients who ever have HCV infection
2. Patients who have received systemic chemotherapies or immunotherapy or molecular target therapies or anticancer Chinese medicine Cinobufacini
3. Patients who have received any local anti-cancer therapy within 4 weeks prior to Cycle 1 treatment
4. Active bleeding (including gastrointestinal bleeding) during the last 4 weeks prior to Cycle 1 treatment
5. Patients with a history of allergy to the known components of YIV-906
6. Known history of human immunodeficiency virus (HIV) seropositivity
7. Known central nervous system metastasis including brain metastasis and meningeal carcinomatosis
8. Hepatocholangiocarcinoma, fibrolamellar cell carcinoma and mixed hepatocellular carcinoma
9. Active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix) within the past 5 years
10. Any severe and/or uncontrolled medical conditions including but not limiting:
1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to Cycle 1 treatment, serious uncontrolled cardiac arrhythmia, uncontrolled hypertension
2. Previous transient ischemic attack (TIA), cerebral vascular accident (CVA), symptomatic peripheral vascular disease (PVD) within last 6 months of Cycle 1 treatment
3. Congenital long QT syndrome
4. Alcoholic patients
5. Acute and chronic, active infectious disorders and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy, in the opinion of the investigator, except chronic HBV
6. Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
7. Patients who have had organ transplantation
11. Patients receiving chronic treatment with corticosteroids (except for intermittent topical or local injection of aldosterone) or other immunosuppressive agents (oral prednisone or equivalent 10 mg/day is allowed to screen).
12. Patients received any blood transfusion, albumin transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), TPO or other medical supportive treatment within 4 weeks of Cycle 1 treatment
13. Patients treated with drugs known to be strong inducers of isoenzyme CYP3A within 7 days of Cycle 1 treatment
14. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from surgery
15. Patients who have received an investigative drug or therapy within the last 4 weeks prior to Cycle 1 treatment
16. Pregnant and/or breastfeeding women
17. Men and women of childbearing age and potential, who are not willing to use effective contraception
18. Unwilling or unable to follow protocol requirements or to give informed consent
19. Ongoing or recent history of autoimmune, uncontrolled psychiatric disorders and drug abuse
20. Uncontrolled hereditary or acquired thrombotic or bleeding disorder
21. Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection
22. Therapeutic dose anticoagulation with warfarin, or similar agents
23. Chronic therapy with nonsteroidal anti-inflammatory agents or other anti-platelet agents. Aspirin at doses up to 100 milligrams/day is permitted
24. No patient, however, may enroll in this trial if they are taking phenytoin (Dilantin)
25. Patients taking traditional Chinese medicines within 14 days prior to taking first dose of study treatment
1. Patients who ever have HCV infection
2. Patients who have received systemic chemotherapies or immunotherapy or molecular target therapies or anticancer Chinese medicine Cinobufacini
3. Patients who have received any local anti-cancer therapy within 4 weeks prior to Cycle 1 treatment
4. Active bleeding (including gastrointestinal bleeding) during the last 4 weeks prior to Cycle 1 treatment
5. Patients with a history of allergy to the known components of YIV-906
6. Known history of human immunodeficiency virus (HIV) seropositivity
7. Known central nervous system metastasis including brain metastasis and meningeal carcinomatosis
8. Hepatocholangiocarcinoma, fibrolamellar cell carcinoma and mixed hepatocellular carcinoma
9. Active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix) within the past 5 years
10. Any severe and/or uncontrolled medical conditions including but not limiting:
1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to Cycle 1 treatment, serious uncontrolled cardiac arrhythmia, uncontrolled hypertension
2. Previous transient ischemic attack (TIA), cerebral vascular accident (CVA), symptomatic peripheral vascular disease (PVD) within last 6 months of Cycle 1 treatment
3. Congenital long QT syndrome
4. Alcoholic patients
5. Acute and chronic, active infectious disorders and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy, in the opinion of the investigator, except chronic HBV
6. Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
7. Patients who have had organ transplantation
11. Patients receiving chronic treatment with corticosteroids (except for intermittent topical or local injection of aldosterone) or other immunosuppressive agents (oral prednisone or equivalent 10 mg/day is allowed to screen).
12. Patients received any blood transfusion, albumin transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), TPO or other medical supportive treatment within 4 weeks of Cycle 1 treatment
13. Patients treated with drugs known to be strong inducers of isoenzyme CYP3A within 7 days of Cycle 1 treatment
14. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from surgery
15. Patients who have received an investigative drug or therapy within the last 4 weeks prior to Cycle 1 treatment
16. Pregnant and/or breastfeeding women
17. Men and women of childbearing age and potential, who are not willing to use effective contraception
18. Unwilling or unable to follow protocol requirements or to give informed consent
19. Ongoing or recent history of autoimmune, uncontrolled psychiatric disorders and drug abuse
20. Uncontrolled hereditary or acquired thrombotic or bleeding disorder
21. Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection
22. Therapeutic dose anticoagulation with warfarin, or similar agents
23. Chronic therapy with nonsteroidal anti-inflammatory agents or other anti-platelet agents. Aspirin at doses up to 100 milligrams/day is permitted
24. No patient, however, may enroll in this trial if they are taking phenytoin (Dilantin)
25. Patients taking traditional Chinese medicines within 14 days prior to taking first dose of study treatment
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yiviva Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yun Yen, MD/PhD
Role: STUDY_CHAIR
Taipei Medical University
Ghassan Abou-Alfa, MD/MBA
Role: STUDY_CHAIR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Calvin Pan. MD Gastroenterology & Hepatology Clinic
Flushing, New York, United States
Site Status
Northwell Monter Cancer Institute
Lake Success, New York, United States
Site Status
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site Status
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site Status
Beijing You'An Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site Status
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Site Status
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Site Status
Foshan Hospital of Traditional Chinese Medicine
Foshan, Guangdong, China
Site Status
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China
Site Status
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Site Status
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Site Status
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Site Status
Hunan Cancer Hospital
Changsha, Hunan, China
Site Status
LongHua Hospital Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Site Status
Shanghai Eastern Hepatobiliary Hospital
Shanghai, Shanghai Municipality, China
Site Status
Shanghai University of Traditional Chinese Medicine Shuguang Hospital
Shanghai, Shanghai Municipality, China
Site Status
Queen Mary Hospital
Hong Kong, , Hong Kong
Site Status
China Medical University Hospital
Taichung, , Taiwan
Site Status
National Cheng Kung University Hospital
Tainan City, , Taiwan
Site Status
Cancer Research Center, Taipei Municipal Wanfang Hospital
Taipei, , Taiwan
Site Status
Taipei Medical University -Shuang Ho Hospital, Ministry of Health and Welfare
Taipei, , Taiwan
Site Status
Taipei Medical University Cancer Center
Taipei, , Taiwan
Site Status
Taipei Veterans General Hospital
Taipei, , Taiwan
Site Status
Chang Gung Memorial Hospital, Linkou
Taoyuan District, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
China
Hong Kong
Taiwan
References
Explore related publications, articles, or registry entries linked to this study.
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu CH, Liu SH, Cheng YC. Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Front Pharmacol. 2018 Nov 19;9:1324. doi: 10.3389/fphar.2018.01324. eCollection 2018.
Reference Type
BACKGROUND
Chu E. Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of PHY906. Oncology (Williston Park). 2018 Feb 15;32(2):e20-e27.
Reference Type
BACKGROUND
Lam W, Jiang Z, Guan F, Huang X, Hu R, Wang J, Bussom S, Liu SH, Zhao H, Yen Y, Cheng YC. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep. 2015 Mar 30;5:9384. doi: 10.1038/srep09384.
Reference Type
BACKGROUND
Rockwell S, Grove TA, Liu Y, Cheng YC, Higgins SA, Booth CJ. Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. Int J Radiat Biol. 2013 Jan;89(1):16-25. doi: 10.3109/09553002.2012.717733. Epub 2012 Sep 3.
Reference Type
BACKGROUND
Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012 Apr 10;140(3):614-23. doi: 10.1016/j.jep.2012.01.047. Epub 2012 Feb 3.
Reference Type
BACKGROUND
Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics. 2011 May 11;4:38. doi: 10.1186/1755-8794-4-38.
Reference Type
BACKGROUND
Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010 Aug 18;2(45):45ra59. doi: 10.1126/scitranslmed.3001270.
Reference Type
BACKGROUND
Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH, Cheng YC. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Feb;73(2):373-80. doi: 10.1007/s00280-013-2359-7. Epub 2013 Dec 3.
Reference Type
RESULT
Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011 Jun;10(2):85-96. doi: 10.1016/j.clcc.2011.03.003. Epub 2011 Apr 22.
Reference Type
RESULT
Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.
Reference Type
RESULT
Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su T, Cheng YC. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009 Oct;29(10):4083-92.
Reference Type
RESULT
Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):253-6. doi: 10.3816/CCC.2003.n.007. No abstract available.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YIV-906-2018L1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
NCT00044512
COMPLETED
PHASE2
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT00105443
COMPLETED
PHASE3
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
NCT01334710
TERMINATED
PHASE2
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
NCT01101906
TERMINATED
PHASE2
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
NCT01666756
COMPLETED
PHASE1
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
NCT01658878
COMPLETED
PHASE1/PHASE2
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
NCT01840592
ACTIVE_NOT_RECRUITING
PHASE2
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
NCT03439891
COMPLETED
PHASE2
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
NCT01774344
COMPLETED
PHASE3
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
NCT00703365
COMPLETED
PHASE2
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
NCT04170556
COMPLETED
PHASE1/PHASE2
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
NCT00976170
COMPLETED
PHASE1
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
NCT03781934
COMPLETED
PHASE1/PHASE2
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
NCT00108953
COMPLETED
PHASE2
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
NCT03059147
TERMINATED
PHASE1
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
NCT01915602
COMPLETED
PHASE2
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
NCT01098760
COMPLETED
PHASE4
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
NCT00997022
COMPLETED
PHASE1
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT04039607
ACTIVE_NOT_RECRUITING
PHASE3
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
NCT00692770
COMPLETED
PHASE3
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT02576509
COMPLETED
PHASE3
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
NCT04044651
WITHDRAWN
PHASE2/PHASE3
Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)
NCT00619541
COMPLETED
PHASE2
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
NCT05048017
RECRUITING
PHASE2